Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.84 |
| ▸ | RAB9A | P51151 | 7/20 | 0.84 |
| ▸ | NPC1 | O15118 | 6/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.75 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.70 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.70 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382530 | 1.00 | MAPT (0.84) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL5147081 | 1.00 | MAPT (0.84) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| Chalcone SCHEMBL25195107 | 0.97 | MAPT (0.80) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL25608287 | 0.92 | MAPT (0.72) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL25267270 | 0.92 | MAPT (0.72) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL108665 | 0.88 | MAPT (0.79) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL28553855 | 0.88 | MAPT (0.79) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL3440510 | 0.87 | MAPT (0.84) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL25209543 | 0.87 | MAPT (0.84) | MAPTRAB9ANPC1CYP2D6CYP3A4 | |
| SCHEMBL3440511 | 0.87 | MAPT (0.84) | MAPTRAB9ANPC1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YewSavin, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20210207175-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-07-08 | — | — | US | disclosed |
| EP-3825409-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-05-26 | — | — | EP | disclosed |
| WO-2019238091-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2019-12-19 | — | — | WO | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-7598294-B2 | Antiproliferative agents; antiinflammatory agents; anticancer agents; diagnosis, therapy | SPEAR THERAPEUTICS LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| EP-0975224-A1 | PROCESS AND COMPOSITIONS FOR ENHANCING RELIABILITY OF EXOGENOUS CHEMICAL SUBSTANCES APPLIED TO PLANTS | MONSANTO COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6020287-A | USING MIXTURE OF HERBICIDE AND PHENYL-SUBSTITUTED OLEFIN COMPOUND | MONSANTO COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1998033385-A1 | PROCESS AND COMPOSITIONS FOR ENHANCING RELIABILITY OF EXOGENOUS CHEMICAL SUBSTANCES APPLIED TO PLANTS | MONSANTO COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
| US-5070001-A | LIGHT-SENSITIVE MIXTURE FOR PRODUCING POSITIVE OR NEGATIVE RELIEF COPIES | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| US-4264483-A | AN ACRYLIC MONOMER OR OLIGOMER, PHOTOREACTIVE RESIN, PHOTOINITIATOR, FREE RADICAL INHIBITOR, PIGMENT | WHITTAKER CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885RAB9A 480/4885NPC1 1378/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885RAB9A 1327/4885NPC1 1908/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885RAB9A 1327/4885NPC1 1908/4885 |
| US-20210207175-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | TET2, ZFX, ZFR | MAPT 4470/4885RAB9A 3127/4885NPC1 156/4885 |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, TFPI, SERPINE1 | MAPT 3522/4885RAB9A 1332/4885NPC1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.